NexImmune (OTCMKTS:NEXI – Get Free Report) will likely be announcing its resultson Monday, August 17th. Analysts expect the company to post earnings of ($13.25) per share for the quarter.
NexImmune Stock Performance
NexImmune stock opened at $0.00 on Friday. NexImmune has a 52 week low of $0.00 and a 52 week high of $2.17.
NexImmune Company Profile
NexImmune, Inc is a clinical‐stage biotechnology company focused on developing novel T‐cell immunotherapies to treat cancer, autoimmune disease and persistent viral infections. The company’s core innovation is its proprietary artificial thymic organoid (ATO) platform, which generates naïve T cells capable of recognizing specific antigens. By guiding T‐cell development in vitro, NexImmune aims to create targeted, high‐potency therapeutic candidates that leverage the body’s natural immune response.
The company’s pipeline includes multiple product candidates at various stages of development.
Read More
- Five stocks we like better than NexImmune
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for NexImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexImmune and related companies with MarketBeat.com's FREE daily email newsletter.
